Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 12/20 | 0.46 |
| ▸ | AKT1 | P31749 | 11/20 | 0.46 |
| ▸ | AKT2 | P31751 | 10/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22308093 | 0.75 | AKT1 (0.49) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL31594759 | 0.75 | AKT1 (0.49) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL31622286 | 0.74 | AKT1 (0.47) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL25195685 | 0.74 | AKT1 (0.48) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL30460118 | 0.74 | AKT1 (0.48) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL22308036 | 0.73 | AKT3 (0.61) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL25403174 | 0.73 | AKT3 (0.64) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL25403166 | 0.73 | AKT3 (0.64) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL22307580 | 0.71 | AKT1 (0.50) | AKT3AKT1AKT2CYP3A4CYP1A2 | |
| SCHEMBL22308403 | 0.71 | AKT1 (0.50) | AKT3AKT1AKT2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144821-A1 | AKT INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3919491-A1 | AKT INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021228223-A1 | DEUTERATED AKT KINASE INHIBITOR | 南京正大天晴制药有限公司 | 2021-11-18 | — | — | WO | disclosed |
| WO-2020156437-A1 | AKT INHIBITOR | 南京正大天晴制药有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144821-A1 | AKT INHIBITOR | AKT2, AKT1, MTOR | AKT3 4/4885AKT1 2/4885AKT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.